FDA Questions First-To-File Exclusivity As Generic Reforms Pass Senate
This article was originally published in The Tan Sheet
Executive Summary
FDA has reservations about the current first-to-file basis for 180-day exclusivity, FDA Chief Counsel Daniel Troy acknowledged at a June 17 Senate Judiciary Committee hearing on generic drug reforms